Wholomics

We’re super excited to announce that Wholomics has been nominated for the regional round of the @Global Startup Awards Edition 11! 🎉 This nomination recognizes our commitment to innovation and impact in the startup ecosystem. Here’s to pushing boundaries and shaping the future! #GSA #CESA #globalstartupawards #GSAnominee

Wholomics participated in the EIT Health Austria Catapult session tonight! Thanks again to the #EITHealthAustria Team for being selected as one of the top startup in Austria!

!!! Support Wholomics at the MassChallenge Community Award !!! Help Wholomics win $25,000 by voting for Wholomics (Patrick Strasser) in the @MassChallenge Community Choice Award! We are working hard to revolutionize Early Cancer Detection and hope to get your support for our presentation live at MC | INNOVATE in #Dallas. Vote Now for Wholomics: https://hubs.li/Q02NZ4kv0 Watch our video here: https://lnkd.in/enF-FmpK

!!! Support Wholomics at the MassChallenge Community Award !!! Help Wholomics win $25,000 by voting for Wholomics (Patrick Strasser) in the @MassChallenge Community Choice Award! We are working hard to revolutionize Early Cancer Detection and hope to get your support for our presentation live at MC | INNOVATE in #Dallas. Vote Now for Wholomics: https://hubs.li/Q02NZ4kv0 Watch our video here: https://lnkd.in/enF-FmpK

As we look back on the past six months, the team at #Wholomics is filled with pride and excitement over the tremendous progress we've made in our mission to revolutionize early cancer detection. From groundbreaking presentations to prestigious program acceptances, it’s been an extraordinary journey! Our journey began with the presentation of our pilot study on early pancreatic cancer detection at the #ASCOGISymposium. The overwhelmingly positive response from the medical community reaffirmed the potential of our proprietary technology to make a significant impact in cancer diagnostics. Building on this momentum, we presented our blinded validation study at the #ASCOAnnualMeeting, the world’s largest cancer conference. This study further validated the efficacy of our technology, showcasing its impressive accuracy in distinguishing between healthy individuals and those with pancreatic cancer. The connections we made and the recognition we received have been invaluable in pushing our mission forward. The culmination of our efforts was being accepted into the #MassChallenge US Early Stage Accelerator. This prestigious program will provide us with the resources, mentorship, and network needed to accelerate our growth and bring our early detection solutions to market faster. We are deeply grateful to our team, partners, and supporters who have been with us on this journey. Together, we are making strides toward a world where cancer is detected early, giving patients the best possible chance for successful treatment and recovery. Stay tuned for more updates as we continue to advance our mission. Here’s to the next six months of innovation and impact!

Exciting Highlights from ASCO 2024 in Chicago! Our team at Wholomics recently had the privilege of attending the ASCO 2024, and what an incredible experience it was! We engaged with a diverse array of experts, including leading oncologists, public health advocates, and industry leaders. Their invaluable insights and feedback have provided us with a deeper understanding of the steps needed to advance our Multi-Cancer Early Detection (MCED) test. One of the key takeaways from the event was the critical role that collaboration plays in driving innovation and improving patient outcomes. A huge thank you to all the leading experts who took the time to meet with us and discuss our future studies. Your support and guidance are instrumental in ensuring that we continue to provide the best science for the benefit of patients. Together, we are making strides towards a future where early detection and improved patient outcomes are within reach. Here's to the power of collaboration and innovation! 🌟 #ASCO2024 #Wholomics #MCED #Innovation #CancerResearch #Collaboration #PatientOutcomes

🌟 Exciting News from Wholomics! 🌟 We're thrilled to present our work at the upcoming ASCO Annual Meeting in Chicago! Join us as we unveil our latest breakthrough: 🔹 Abstract Title: Independent blinded validation of a novel blood-based early pancreatic cancer detection test. 📍 Poster Board Number: 146 📅 Session Date/Time: June 1, 2024, 1:30 PM - 4:30 PM CDT In this landmark study, our dual-cohort design achieved an impressive 94.6% accuracy in our training cohort and 92.5% in the blinded validation cohort for detecting early pancreatic cancer. We reached a specificity of 95% with only a single false positive and a sensitivity of 91.7%. Stop by our poster to dive into the data and discuss how this could change the future of cancer diagnostics. 👋 Come chat with us and explore collaboration opportunities! #ASCO24 #CancerResearch #EarlyDetection #PancreaticCancer #InnovationInOncology

Meet our team! We are looking forward to meeting you in May and June in Berlin, Chicago, and Munich. In May 14th-16th you can find our Wholomics team at the Deep Tech Momentum in Berlin, a 3-day bootcamp for the Top 100 European early-stage Deep Tech start-ups. It is a pleasure and honor for us to be recognized as a top potential start-up in tech! From May 31st to June 4th we will join the ASCO Annual Meeting in Chicago where we will present the results of our latest blinded pancreatic cancer validation study. In June 5th-6th we will be at the Health.tech conference in Munich, and we would love to network and exchange ideas with you!

Our last equIP Start-up Night: BioTech Special in corporation with red-stars.com data AG was a huge success!   The discussions about the megatrends in the BioTech sector, the current legal developments and the presentations of innovative start-ups gave us deep insights into the future of this exciting industry.   Special thanks go to our outstanding keynote speaker, legal experts, panellists and start-ups who shared their expertise and passion with us.   Let's move the BioTech industry forward together!   Start-ups: a:head bio AG, Rockfish Bio, HeartBeat.bio AG, Wholomics, Ablevia biotech GmbH, imd BIOTECH GmbH   Interviews mit Johannes Grillari (Rockfish Bio), Maximilian Schneider (Wholomics), Kambis Kohansal Vajargah (Wirtschaftskammer Österreich)   Nähere Informationen zum CMS equIP Programm finden Sie hier: https://lnkd.in/g79xSEWh #startup #innovation #equip #BioTech

🚀 Big News from Wholomics! 🚀 We're absolutely thrilled to announce that we were selected as one of Europe’s top 100 early-stage Deep Tech startups! We're joining the prestigious Deep Tech Momentum 2024 in Berlin, a testament to the innovation and hard work our team has been dedicated to. Being chosen from over a thousand startups is not just an honor; it's a milestone that marks us as a part of the Deep Tech future of Europes. We're excited to share this journey with you and invite you to follow us! Stay tuned for updates, insights, and behind-the-scenes looks as we gear up for Deep Tech Momentum. Let's shape the future of Deep Tech, together.